| __timestamp | ACADIA Pharmaceuticals Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 122000 |
| Thursday, January 1, 2015 | 76369000 | 1896000 |
| Friday, January 1, 2016 | 4406000 | 2699000 |
| Sunday, January 1, 2017 | 13060000 | 1702000 |
| Monday, January 1, 2018 | 18330000 | 471000 |
| Tuesday, January 1, 2019 | 19598000 | 4101000 |
| Wednesday, January 1, 2020 | 20550000 | 1676000 |
| Friday, January 1, 2021 | 19141000 | 7264000 |
| Saturday, January 1, 2022 | 10166000 | 6594000 |
| Sunday, January 1, 2023 | 45731000 | 4661000 |
Cracking the code
In the ever-evolving landscape of biopharmaceuticals, understanding the cost of revenue is crucial for assessing a company's financial health. Over the past decade, ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue. From 2014 to 2023, ACADIA's cost of revenue fluctuated significantly, peaking in 2015 with a 76% increase from the previous year, before experiencing a notable decline in 2016. In contrast, BioCryst's cost of revenue remained relatively stable, with a modest increase of around 5% annually, except for a sharp rise in 2021. This divergence highlights the different strategic approaches these companies have taken in managing their production costs. As the biopharmaceutical industry continues to grow, monitoring these financial metrics will be essential for investors and stakeholders alike.
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and ACADIA Pharmaceuticals Inc.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Catalent, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down ADMA Biologics, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Xencor, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored